AU2001285318A1 - Use of an aldosterone receptor antagonist to improve cognitive function - Google Patents

Use of an aldosterone receptor antagonist to improve cognitive function

Info

Publication number
AU2001285318A1
AU2001285318A1 AU2001285318A AU8531801A AU2001285318A1 AU 2001285318 A1 AU2001285318 A1 AU 2001285318A1 AU 2001285318 A AU2001285318 A AU 2001285318A AU 8531801 A AU8531801 A AU 8531801A AU 2001285318 A1 AU2001285318 A1 AU 2001285318A1
Authority
AU
Australia
Prior art keywords
receptor antagonist
aldosterone receptor
cognitive function
improve cognitive
aldosterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001285318A
Other languages
English (en)
Inventor
Kenton N. Fedde
Alfonzo T Perez
Joseph F Tooley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of AU2001285318A1 publication Critical patent/AU2001285318A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001285318A 2000-08-28 2001-08-28 Use of an aldosterone receptor antagonist to improve cognitive function Abandoned AU2001285318A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22873800P 2000-08-28 2000-08-28
US60/228,738 2000-08-28
PCT/US2001/026760 WO2002017895A2 (en) 2000-08-28 2001-08-28 Use of an aldosterone receptor antagonist to improve cognitive function

Publications (1)

Publication Number Publication Date
AU2001285318A1 true AU2001285318A1 (en) 2002-03-13

Family

ID=22858397

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001285318A Abandoned AU2001285318A1 (en) 2000-08-28 2001-08-28 Use of an aldosterone receptor antagonist to improve cognitive function

Country Status (10)

Country Link
US (2) US20020111337A1 (da)
EP (1) EP1313485B1 (da)
JP (1) JP2004507495A (da)
AT (1) ATE306272T1 (da)
AU (1) AU2001285318A1 (da)
CA (1) CA2419256A1 (da)
DE (1) DE60114027T2 (da)
DK (1) DK1313485T3 (da)
ES (1) ES2251505T3 (da)
WO (1) WO2002017895A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193172B2 (en) 2001-11-23 2012-06-05 Pop Test Cortisol Llc Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists
UA87437C2 (ru) * 2002-04-26 2009-07-27 Бристол-Майерс Сквибб Компани Айседжен Инк Лечение гипертензии у женщин, которые поддаются гормонзаместительной терапии
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
PT1558265E (pt) * 2002-11-05 2010-03-22 Bayer Schering Pharma Ag Utilização da drospirenona para o tratamento da hipertensão
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
US20060167026A1 (en) * 2003-01-06 2006-07-27 Hiroyuki Nawa Antipsychotic molecular-targeting epithelial growth factor receptor
US7485094B2 (en) * 2003-09-30 2009-02-03 Smithmarks, Inc. Methods of diagnosis using pulse volume measurement
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US20090265215A1 (en) * 2008-04-22 2009-10-22 Paul Bernhard Lindstrom Methods and apparatus to monitor audience exposure to media using duration-based data
WO2012059594A1 (en) * 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
US8933113B2 (en) 2011-01-20 2015-01-13 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2012139495A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
US9193717B2 (en) 2011-10-13 2015-11-24 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
EP2765859B1 (en) 2011-10-13 2017-01-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
EP2765858B1 (en) 2011-10-13 2016-08-03 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
AR091731A1 (es) 2012-07-19 2015-02-25 Merck Sharp & Dohme Antagonistas del receptor de mineralocorticoides
EP3373920A4 (en) * 2015-11-13 2019-07-17 Pietro Paolo Sanna METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO ALCOHOL CONSUMPTION

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133012A (en) * 1961-06-28 1964-05-12 Universal Oil Prod Co Combination catalytic reforming process
US3257390A (en) * 1963-06-12 1966-06-21 Merck & Co Inc Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
AU538186B2 (en) * 1980-03-07 1984-08-02 Scotia Holdings Plc Prostaglandin precursors
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
DE3506100A1 (de) * 1985-02-18 1986-08-21 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
ES2293944T3 (es) * 1996-12-11 2008-04-01 G.D. Searle Llc. Procedimiento de epoxidacion.
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
CZ20011590A3 (cs) * 1998-11-06 2003-01-15 G. D. Searle & Co. Léčivo pro léčení kardiovaskulárních poruch a kompozice s obsahem inhibitoru enzymu konvertujícího angiotensin, antagonisty aldosteronu, kličkového diuretika a digoxinu
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
DE60024335T2 (de) * 1999-03-05 2006-08-03 G.D. Searle Llc, Chicago Kombinationstherapie von Angiotensin-konvertierendem Enzymhemmer und Epoxy-steroidalem Aldosteron Antagonist zur Behandlung von kardiovaskulären Erkrankungen

Also Published As

Publication number Publication date
DE60114027D1 (de) 2006-02-23
EP1313485B1 (en) 2005-10-12
US20020111337A1 (en) 2002-08-15
ATE306272T1 (de) 2005-10-15
EP1313485A2 (en) 2003-05-28
WO2002017895A3 (en) 2003-02-06
DK1313485T3 (da) 2005-12-27
US20060058274A1 (en) 2006-03-16
JP2004507495A (ja) 2004-03-11
ES2251505T3 (es) 2006-05-01
WO2002017895A2 (en) 2002-03-07
CA2419256A1 (en) 2002-03-07
DE60114027T2 (de) 2006-07-13

Similar Documents

Publication Publication Date Title
AU2001285318A1 (en) Use of an aldosterone receptor antagonist to improve cognitive function
MXPA04000586A (es) Combinacion de un atagonista del receptor de aldosterona con un inhibidor de la hmg coa reductasa.
AU3652102A (en) Compounds and their uses
YU20600A (sh) Nova upotreba antagonista 5-ht3 receptora
MY143366A (en) Muscarinic acetylcholine receptor antagonists
WO2003029262A3 (en) The human mob-5 (il-24) receptors and uses thereof
IL155703A0 (en) Treatment of sexual dysfunction with non peptide bombesin receptor antagonists
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
SG149872A1 (en) Antagonists of the bradykinin b1 receptor
MXPA06000662A (es) Antagonistas del receptor muscarinico de acetilcolina.
TW200519109A (en) Muscarinic acetylcholine receptor antagonists
TW200519108A (en) Muscarinic acetylcholine receptor antagonists
MY137620A (en) Therapeutic treatment
HK1028197A1 (en) Combination therapy for modulating the human sexual response
WO2002011732A8 (en) Novel bicyclic and tricyclic pyrrolidine derivatives as gnrh antagonists
AU1604001A (en) Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
MXPA05007605A (es) Antagonista del receptor de androgenos.
EP1246619A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
CA2416879A1 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
AU6503900A (en) Chemokine receptor antagonists and methods of use therefor
AU6389900A (en) Chemokine receptor antagonists and methods of use therefor
AU2002302735A1 (en) 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists
ZA200403530B (en) Chemokine receptor antagonists and methods of use thereof.
AU4546900A (en) Estrogen receptors and bone